CIK 0001802768 · Large accelerated filer
Royalty Pharma plc
Sign in to watch- Ticker
- RPRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- (212) 883-0200
- Business address
- 110 EAST 59TH STREET, NEW YORK, NY, 10022
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,324,753
- in 4 filings, $12.3M under 10b5-1 plans
Net −$12,324,753. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-06 | Urist Marshall EVP, Research & Investments | Conversion | +150,000 | 150,000 | ||
| 2026-11-06 | Urist Marshall EVP, Research & Investments | Conversion · LP interests in RPI US Partners 2019, LP | −15,000 | 229,412 | ||
| 2026-11-06 | Coyne Terrance P. EVP & CFO | Conversion | +150,000 | 150,000 | ||
| 2026-11-06 | Coyne Terrance P. EVP & CFO | Conversion | +100,000 | 100,000 | ||
| 2026-11-06 | Coyne Terrance P. EVP & CFO | Conversion · LP interests in RPI US Partners 2019, LP | −15,000 | 102,526 | ||
| 2026-11-06 | Coyne Terrance P. EVP & CFO | Conversion · LP interests in RPI US Partners 2019, LP | −10,000 | 473,942 | ||
| 2026-11-04 | Urist Marshall EVP, Research & Investments | Grant or award | +5,341 | 5,341 | ||
| 2026-11-04 | Coyne Terrance P. EVP & CFO | Grant or award | +7,122 | 7,122 | ||
| 2026-11-04 | Hite Christopher EVP & Chairman, Partnering | Grant or award | +7,122 | 277,523 | ||
| 2026-11-04 | Legorreta Pablo G. CEO, Chairman of the Board | Grant or award | +42,209 | 1,350,029 | ||
| 2026-10-05 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 | −4,126 | $57.10 | $236K | 0 |
| 2026-09-30 | Bassler Bonnie L Director | Grant or award | +642 | $58.41 | $37K | 79,823 |
| 2026-09-28 | Urist Marshall EVP, Research & Investments | Sale 10b5-1 | −4,126 | $57.88 | $239K | 4,126 |
| 2026-09-22 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 | −96,073 | $58.51 | $5.6M | 274,328 |
| 2026-09-22 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 | −3,927 | $58.93 | $231K | 270,401 |
| 2026-08-19 | Hite Christopher EVP & Chairman, Partnering | Gift 10b5-1 | −16,800 | 23,200 | ||
| 2026-08-18 | Hite Christopher EVP & Chairman, Partnering | Sale 10b5-1 | −100,000 | $59.97 | $6.0M | 370,401 |
| 2026-08-13 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −9,230 | $58.59 | $541K | 1,772 |
| 2026-08-13 | Coyne Terrance P. EVP & CFO | Sale 10b5-1 | −1,772 | $59.14 | $105K | 0 |
| 2026-08-07 | Urist Marshall EVP, Research & Investments | Gift · LP interests in RPI US Partners 2019, LP | −3,000 | 244,412 |
Page 1 of 8 · 159 trades